Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down while Keeping an Eye on the Enemy

Clinical Colorectal Cancer

Volumn 15, Issue 1, 2016, Pages 7-15

  Aprile, Giuseppe ^a   Giuliani, Francesco ^b   Lutrino, Stefania Eufemia ^c   Fontanella, Caterina ^a   Bonotto, Marta ^a   Rihawi, Karim ^a   Fasola, Gianpiero ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c Division of Medical Oncology   (Italy)

Author keywords

Bevacizumab; Colorectal cancer; Efatutazone; EGFR inhibitors; Erlotinib; Maintenance; MGN1703; Treatment duration

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EFATUTAZONE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; LEFITOLIMOD; PANITUMUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CAMPTOTHECIN; DNA; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RESISTANCE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE CHEMOTHERAPY; METASTATIC COLORECTAL CANCER; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; INDUCTION CHEMOTHERAPY; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA; ERLOTINIB HYDROCHLORIDE; FLUOROURACIL; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE;

EID: 84960110381     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.08.002     Document Type: Review

References (121)

1. A.P. Venook, D. Niedzwiecki, H.J. Lenz, and et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) J Clin Oncol 32 suppl 5 2014 abstract LBA3
2. C. Cremolini, F. Loupakis, C. Antoniotti, and et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study Lancet Oncol 2015 pii: S1470-2045(15)00122-9
3. G. Aprile, S.E. Lutrino, L. Ferrari, and et al. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients World J Gastroenterol 19 2013 8474 8488
4. H. Brenner, M. Kloor, and C.P. Pox Colorectal cancer Lancet 383 2014 1490 1502
5. F. Giuliani, F. De Vita, G. Colucci, and et al. Maintenance therapy in colon cancer Cancer Treat Rev 36 suppl 3 2010 S42 S45
6. L.H. Simkens, M. Koopman, and C.J. Punt Optimal duration of systemic treatment in metastatic colorectal cancer Curr Opin Oncol 26 2014 448 453
7. M. Seymour Conceptual approaches to metastatic disease Ann Oncol 23 suppl 10 2012 x77 x80
8. A. Falcone, S. Ricci, I. Brunetti, and et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 2007 1670 1676
9. D. Marino, F. Leone, F. D'Avanzo, and et al. Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy Crit Rev Oncol Hematol 92 2014 218 226
10. E. Van Cutsem, A. Cervantes, B. Nordlinger, et al. ESMO Guidelines Working Group Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 suppl 3 2014 iii1 iii9
11. P.M. Fidias, S.R. Dakhil, A.P. Lyss, and et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 2009 591 598
12. L.G. Paz-Ares, F. de Marinis, M. Dediu, and et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer J Clin Oncol 31 2013 2895 2902
13. J. Gligorov, D. Doval, J. Bines, and et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial Lancet Oncol 15 2014 1351 1360
14. R.A. Burger, M.F. Brady, M.A. Bookman, and et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
15. T.J. Perren, A.M. Swart, J. Pfisterer, and et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
16. T. Troiani, E. Martinelli, S. Napolitano, and et al. Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer Curr Med Chem 21 2014 1639 1653
17. G.S. Sharp, and W.W. Benefiel 5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum Cancer Chemother Rep 20 1962 97 101
18. Y. Sugimoto, Y. Ohe, K. Nishio, and et al. In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines Cancer Chemother Pharmacol 30 1992 417 422
19. D. Salonga, K.D. Danenberg, M. Johnson, and et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res 6 2000 1322 1327
20. L. Leichman, H.J. Lenz, C.G. Leichman, and et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial Eur J Cancer 31A 1995 1306 1310
21. C.G. Leichman, H.J. Lenz, L. Leichman, and et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J Clin Oncol 15 1997 3223 3229
22. L.X. Qiu, Q.Y. Tang, J.L. Bai, and et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine based chemotherapy: evidence from 24 studies Int J Cancer 123 2008 2384 2389
23. P.R. Subbarayan, M. Sarkar, G. Nelson, and et al. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance Anticancer Res 30 2010 1149 1156
24. M. Fukushima, K. Sakamoto, H. Ohshimo, and et al. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase Oncol Rep 24 2010 835 842
25. K.H. Yeh, A.L. Cheng, J.P. Wan, and et al. Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells Anticancer Drugs 15 2004 371 376
26. R. Hofheinz, G. Hartung, S. Samel, and et al. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer - a phase II study Anticancer Drugs 13 2002 999 1004
27. U. Graeven, D. Arnold, A. Reinacher-Schick, and et al. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma Onkologie 30 2007 169 174
28. A. de Gramont, J. Vignoud, C. Tournigand, and et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer Eur J Cancer 33 1997 214 219
29. T. André, C. Louvet, E. Raymond, and et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen Ann Oncol 9 1998 1251 1253
30. T. André, M.A. Bensmaine, C. Louvet, and et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen J Clin Oncol 17 1999 3560 3568
31. J. Cassidy, S. Clarke, E. Díaz-Rubio, and et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results Br J Cancer 105 2011 58 64
32. F. Montagnani, A. Chiriatti, G. Turrisi, and et al. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity Colorectal Dis 13 2011 846 852
33. M. Alagoz, D.C. Gilbert, S. El-Khamisy, and et al. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets Curr Med Chem 19 2012 3874 3885
34. A. Petitprez, and A.K. Larsen Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models Curr Pharm Des 19 2013 958 964
35. D. Cunningham, Y. Humblet, S. Siena, and et al. Cetuximab mono-therapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
36. J. Souglakos, A. Kalykaki, L. Vamvakas, and et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy Ann Oncol 18 2007 305 310
37. D. Balin-Gauthier, J.P. Delord, M.J. Pillaire, and et al. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation Br J Cancer 98 2008 120 128
38. S. Benvenuti, A. Sartore-Bianchi, F. Di Nicolantonio, and et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2007 2643 2648
39. W. De Roock, B. Claes, D. Bernasconi, and et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
40. F. Perrone, A. Lampis, M. Orsenigo, and et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 2009 84 90
41. C. Bokemeyer, E. Van Cutsem, P. Rougier, and et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 2012 1466 1475
42. J.Y. Douillard, A. Rong, and R. Sidhu RAS mutations in colorectal cancer N Engl J Med 369 2013 2159 2160
43. F. Di Nicolantonio, M. Martini, F. Molinari, and et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
44. S.M. Leto, and L. Trusolino Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies J Mol Med (Berl) 92 2014 709 722
45. R. Giampieri, M. Scartozzi, M. Del Prete, and et al. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation Crit Rev Oncol Hematol 88 2013 272 283
46. W.J. Jeong, P.H. Cha, and K.Y. Choi Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer World J Gastroenterol 20 2014 9862 9871
47. A. Bardelli, and S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
48. C. Montagut, A. Dalmases, B. Bellosillo, and et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer Nat Med 18 2012 221 223
49. T. Troiani, S. Napolitano, D. Vitagliano, and et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition Clin Cancer Res 20 2014 3775 3786
50. B.O. Van Emburgh, A. Sartore-Bianchi, F. Di Nicolantonio, and et al. Acquired resistance to EGFR-targeted therapies in colorectal cancer Mol Oncol 8 2014 1084 1094
51. E. Crowley, F. Di Nicolantonio, F. Loupakis, and et al. Liquid biopsy: monitoring cancer-genetics in the blood Nat Rev Clin Oncol 10 2013 472 484
52. K.K. Ciombor, and J. Berlin Targeting metastatic colorectal cancer - present and emerging treatment options Pharmgenomics Pers Med 7 2014 137 144
53. A. Bagri, L. Berry, B. Gunter, and et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy Clin Cancer Res 16 2010 3887 3900
54. V.F. Mautner, R. Nguyen, R. Knecht, and et al. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation Ann Oncol 21 2010 2294 2295
55. M.R. Mancuso, R. Davis, S.M. Norberg, and et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2006 2610 2621
56. T. Powles, I. Kayani, K. Sharpe, and et al. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer Ann Oncol 24 2013 2098 2103
57. D.L. Roberts, K.J. Williams, R.L. Cowen, and et al. Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells Br J Cancer 101 2009 1290 1297
58. X.X. Han, C.M. Guo, Y. Li, and et al. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α Mol Vis 18 2012 1 9
59. P. Mésange, V. Poindessous, M. Sabbah, and et al. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor Oncotarget 5 2014 4709 4721
60. J. Capdevila, A. Carrato, J. Tabernero, and et al. What could nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Crit Rev Oncol Hematol 92 2014 83 106
61. G. Bocci, and F. Loupakis The possible role of chemotherapy in antiangiogenic drug resistance Med Hypotheses 78 2012 646 648
62. Y. Wu, K. Lucia, M. Lange, and et al. Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas J Neurooncol 119 2014 263 273
63. T.S. Maughan, R.D. James, D.J. Kerr, and et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomized trial Lancet 361 2003 457 464
64. R.A. Adams, A.M. Meade, M.T. Seymour, and et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase III MRC COIN trial Lancet Oncol 12 2011 642 653
65. S.R. Berry, R. Cosby, T. Asmis, and et al. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis Ann Oncol 26 2015 477 485
66. R. Labianca, A. Sobrero, L. Isa, and et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomized GISCAD trial Ann Oncol 22 2011 1236 1242
67. G. Aprile, M. Mazzer, S. Moroso, and et al. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer Anticancer Drugs 20 2009 217 229
68. C. Tournigand, A. Cervantes, A. Figer, and et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer. A GERCOR study J Clin Oncol 24 2006 394 400
69. B. Chibaudel, F. Maindrault-Goebel, G. Lledo, and et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study J Clin Oncol 27 2009 5727 5733
70. L.B. Saltz, S. Clarke, E. Díaz-Rubio, and et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
71. H.S. Hochster, A. Grothey, L. Hart, and et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT Ann Oncol 25 2014 1172 1178
72. E. Díaz-Rubio, A. Gómez-España, B. Massutí, and et al. First-line XELOX plus bevacizumab followes by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study Oncologist 17 2012 15 25
73. L.H. Simkens, H. van Tinteren, A. May, and et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group Lancet 385 2015 1843 1852
74. S. Hegewisch-Becker, U. Graeven, C.A. Lerchenmüller, and et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial Lancet Oncol 2015 pii: S1470-2045(15)00042-X
75. D. Koeberle, D.C. Betticher, R. Von Moos, and et al. Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non inferiority trial (SAKK 41/06) J Clin Oncol suppl 2013 abstract 3503
76. A.A.L. Pereira, J.F.M. Rego, P.M. Hoff, and et al. The effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer: a meta-analysis of randomized trials J Clin Oncol 32 suppl 5 2014 3542
77. G. Aprile, M. Macerelli, and F. Giuliani Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor BioDrugs 27 2013 213 224
78. E. Martinelli, T. Troiani, F. Venturini, and et al. Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial) J Clin Oncol 33 suppl 3 2015 abstract TPS789
79. J. Mendelsohn, and J. Baselga Epidermal growth factor receptor targeting in cancer Semin Oncol 33 2006 369 385
80. H. Wasan, A.M. Meade, R. Adams, and et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial Lancet Oncol 15 2014 631 639
81. R. Bianco, S. Garofalo, R. Rosa, and et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs Br J Cancer 98 2008 923 930
82. F. Loupakis, C. Cremolini, G. Fontanini, and et al. Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer Ther Adv Med Oncol 1 2009 167 181
83. R. Giampieri, G. Aprile, M. Del Prete, and et al. Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients Curr Drug Targets 15 2014 1225 1230
84. L. Salvatore, F. Loupakis, C. Cremolini, and et al. Phase II randomized study of induction FOLFOXIRI plus bevacizumab (Bev) followed by maintenance with Bev alone or Bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): the MOMA trial J Clin Oncol 32 suppl 5 2014 abstract TPS3664
85. ERbitux MEtastatic colorectal cancer Strategy Study: a phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer [EudraCT no. 2014-004299-41]. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004299-41/IT. Accessed: April 12, 2015.
86. G.N. Naumov, M.B. Nilsson, T. Cascone, and et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance Clin Cancer Res 15 2009 3484 3494
87. L.B. Saltz, H.J. Lenz, H.L. Kindler, and et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared to cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561
88. C. Tournigand, B. Chibaudel, B. Samson, and et al. Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to k-ras status: results of the GERCOR DREAM phase III trial J Clin Oncol suppl 2013 abstract 3515
89. H.J. Schmoll, B. Wittig, D. Arnold, and et al. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial J Cancer Res Clin Oncol 140 2014 1615 1624
90. H.J. Schmoll, J. Riera-Knorrenschild, H.G. Kopp, and et al. Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: a subgroup with improved overall survival J Clin Oncol 33 suppl 3 2015 abstract 680
91. D. Cunningham, A. Zurlo, R. Salazar, and et al. IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: immunomodulatory maintenance therapy with TLR-9 agonist MGN1703 J Clin Oncol 33 suppl 3 2015 abstract TPS791
92. B. Zou, and B.C. Qiao L,Wong Current understanding of the role of PPARγ in gastrointestinal cancers PPAR Res 2009 2009 816957
93. Y. Komatsu, T. Yoshino, K. Yamazaki, and et al. Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer Invest New Drugs 32 2014 473 480
94. E. Boucher, I. Davidenko, I. Hadler, and et al. Randomised, placebo-controlled, phase 2 study of efatutazone maintenance therapy in patients with advanced colorectal cancer who have achieved disease control following first-line chemotherapy 25-28 June, 2014 Paper presented at: World Congress on Gastrointestinal Cancers Barcelona, Spain
95. K. Lien, S. Georgsdottir, L. Sivanathan, and et al. Low-dose metronomic chemotherapy: a systematic literature analysis Eur J Cancer 49 2013 3387 3395
96. Y.B. Hao, S.Y. Yi, J. Ruan, and et al. New insights into metronomic chemotherapy-induced immunoregulation Cancer Lett 354 2014 220 226
97. N. André, M. Carré, and E. Pasquier Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11 2014 413 431
98. A. Gnoni, N. Silvestris, A. Licchetta, and et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol 95 2015 46 61
99. G. Bocci, K.C. Nicolaou, and R.S. Kerbel Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs Cancer Res 62 2002 6938 6943
100. C. Louvet, A.M. Coudray, C. Tournigand, and et al. Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice Anticancer Drugs 11 2000 579 582
101. H. Tsujimoto, S. Tsukioka, S. Ono, and et al. Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase Oncol Lett 1 2010 973 980
102. K. Kolinsky, B.Q. Shen, Y.E. Zhang, and et al. In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancerxenograft models Mol Cancer Ther 8 2009 75 82
103. C. Hackl, S. Man, G. Francia, and et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models Gut 62 2013 259 271
104. R. Petrioli, A. Pascucci, E. Francini, and et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors Anticancer Drugs 19 2008 91 96
105. M. Nannini, E. Nobili, R. Di Cicilia, and et al. To widen the setting of cancer patients who could benefit from metronomic capecitabine Cancer Chemother Pharmacol 64 2009 189 193
106. R.K. Kelley, J. Hwang, M.J. Magbanua, and et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer Br J Cancer 109 2013 1725 1734
107. F. Pietrantonio, P. Biondani, A. Pellegrinelli, and et al. Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab Med Oncol 29 2012 2838 2841
108. K. Norrby Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth? APMIS 122 2014 565 579
109. R. Jagsi, D.P. Sulmasy, and B. Moy Value of cancer care: ethical considerations for the practicing oncologist Am Soc Clin Oncol Educ Book 2014 e146 e149
110. H.E. Carter, D. Zannino, R. John Simes, and et al. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study Eur J Cancer 50 2014 535 543
111. S. Whyte, A. Pandor, and M. Stevenson Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal Pharmacoeconomics 30 2012 1119 1132
112. A. Lange, A. Prenzler, M. Frank, and et al. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer Eur J Cancer 50 2014 40 49
113. D. Lawrence, M. Maschio, K.J. Leahy, and et al. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC) J Med Econ 16 2013 1387 1398
114. E.M. Ewara, G.S. Zaric, S. Welch, and et al. Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer Curr Oncol 21 2014 e541 e550
115. V. Shankaran, D. Mummy, L. Koepl, and et al. Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer Oncologist 19 2014 892 899
116. E. Díaz-Rubio, F. Pietrantonio, and F. de Braud Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer Oncologist 17 2012 1426 1428
117. G. Fasola, G. Aprile, L. Marini, and et al. Drug waste minimization as an effective strategy of cost-containment in oncology BMC Health Serv Res 14 2014 57
118. S.M. Francis, A. Heyliger, M.A. Miyares, and et al. Potential cost savings associated with dose rounding antineoplastic monoclonal agents J Oncol Pharm Practice 21 2015 280 284
119. P.J. Neumann, J.T. Cohen, and M.C. Weinstein Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold N Engl J Med 371 2014 796 797
120. J. Lipscomb, K.R. Yabroff, M.C. Hornbrook, and et al. Comparing cancer care, outcomes, and costs across health systems: charting the course J Natl Cancer Inst Monogr 2013 2013 124 130
121. A. Sobrero, and P. Bruzzi Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval J Clin Oncol 27 2009 5868 5873